{"id":"neridronic-acid","rwe":[{"pmid":"38506956","year":"2024","title":"Paget Disease of Bone Harboring Bone Metastatic Neuroendocrine Cancer: A Case Report.","finding":"","journal":"Calcified tissue international","studyType":"Clinical Study"},{"pmid":"32176416","year":"2020","title":"Treatment with bisphosphonates to mitigate calcification of elastin-containing bioprosthetic materials.","finding":"","journal":"Journal of biomedical materials research. Part A","studyType":"Clinical Study"},{"pmid":"29230158","year":"2017","title":"Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.","finding":"","journal":"Molecular syndromology","studyType":"Clinical Study"},{"pmid":"27939801","year":"2017","title":"First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.","finding":"","journal":"Joint bone spine","studyType":"Clinical Study"},{"pmid":"19761412","year":"2009","title":"Neridronic acid for the treatment of bone metabolic diseases.","finding":"","journal":"Expert opinion on drug metabolism & toxicology","studyType":"Clinical Study"}],"tags":[{"label":"neridronic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Farnesyl pyrophosphate synthase","category":"target"},{"label":"FDPS","category":"gene"},{"label":"Active","category":"status"},{"label":"Humoral hypercalcemia of malignancy","category":"indication"},{"label":"Osteoporosis","category":"indication"}],"phase":"phase_3","safety":{"commonSideEffects":[{"effect":"Headache","drugRate":"20.6%","placeboRate":"","totalAtRisk":316,"totalAffected":65,"trialsReporting":1},{"effect":"Myalgia","drugRate":"16.5%","placeboRate":"","totalAtRisk":316,"totalAffected":52,"trialsReporting":1},{"effect":"Nausea","drugRate":"10.8%","placeboRate":"","totalAtRisk":316,"totalAffected":34,"trialsReporting":1},{"effect":"Fatigue","drugRate":"10.1%","placeboRate":"","totalAtRisk":316,"totalAffected":32,"trialsReporting":1},{"effect":"Condition aggravated","drugRate":"9.5%","placeboRate":"","totalAtRisk":316,"totalAffected":30,"trialsReporting":1},{"effect":"Pain","drugRate":"8.9%","placeboRate":"","totalAtRisk":316,"totalAffected":28,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"8.5%","placeboRate":"","totalAtRisk":316,"totalAffected":27,"trialsReporting":1},{"effect":"Back pain","drugRate":"7.9%","placeboRate":"","totalAtRisk":316,"totalAffected":25,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"7.9%","placeboRate":"","totalAtRisk":316,"totalAffected":25,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"5.7%","placeboRate":"","totalAtRisk":316,"totalAffected":18,"trialsReporting":1},{"effect":"Bone pain","drugRate":"5.4%","placeboRate":"","totalAtRisk":316,"totalAffected":17,"trialsReporting":1}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"neridronate","offLabel":[],"synonyms":["neridronic acid","neridronate"],"timeline":[],"approvals":[],"brandName":"Neridronate","ecosystem":[{"indication":"Humoral hypercalcemia of malignancy","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium gluconate","slug":"calcium-gluconate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""}],"globalPrevalence":200000000}],"mechanism":{"target":"Farnesyl pyrophosphate synthase","targets":[{"gene":"FDPS","source":"DrugCentral","target":"Farnesyl pyrophosphate synthase","protein":"Farnesyl pyrophosphate synthase"}],"modality":"Small Molecule","drugClass":"neridronic acid","explanation":"Think of bone resorption like a construction site where old buildings are torn down to make way for new ones. Farnesyl pyrophosphate synthase is like the bulldozer that helps break down the old buildings. Neridronate is like a brake that slows down the bulldozer, allowing the old buildings to remain intact and reducing the risk of bone loss.","oneSentence":"Neridronate works by inhibiting the enzyme Farnesyl pyrophosphate synthase, which plays a crucial role in bone resorption.","technicalDetail":"Neridronate specifically inhibits the enzyme Farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and plays a critical role in the biosynthesis of isoprenoids, including farnesyl pyrophosphate, a key intermediate in the prenylation of proteins involved in bone resorption."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3377","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NERIDRONIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NERIDRONIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:56:04.702943","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:42:13.989752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"alendronic acid","drugSlug":"alendronic-acid","fdaApproval":"1995-09-29","relationship":"same-target"},{"drugName":"ibandronic acid","drugSlug":"ibandronic-acid","fdaApproval":"2003-05-16","relationship":"same-target"},{"drugName":"pamidronic acid","drugSlug":"pamidronic-acid","fdaApproval":"1991-10-31","relationship":"same-target"},{"drugName":"risedronic acid","drugSlug":"risedronic-acid","fdaApproval":"1998-03-27","relationship":"same-target"},{"drugName":"sodium pyrophosphate","drugSlug":"sodium-pyrophosphate","fdaApproval":"","relationship":"same-target"},{"drugName":"zoledronic acid","drugSlug":"zoledronic-acid","fdaApproval":"2001-08-20","patentExpiry":"Feb 5, 2028","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"neridronic acid","indications":{"approved":[{"name":"Humoral hypercalcemia of malignancy","source":"DrugCentral","snomedId":47709007,"regulator":"FDA"},{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alendronic-acid","brandName":"alendronic acid","genericName":"alendronic acid","approvalYear":"1995","relationship":"same-target"},{"drugId":"ibandronic-acid","brandName":"ibandronic acid","genericName":"ibandronic acid","approvalYear":"2003","relationship":"same-target"},{"drugId":"pamidronic-acid","brandName":"pamidronic acid","genericName":"pamidronic acid","approvalYear":"1991","relationship":"same-target"},{"drugId":"risedronic-acid","brandName":"risedronic acid","genericName":"risedronic acid","approvalYear":"1998","relationship":"same-target"},{"drugId":"sodium-pyrophosphate","brandName":"sodium pyrophosphate","genericName":"sodium pyrophosphate","approvalYear":"","relationship":"same-target"},{"drugId":"zoledronic-acid","brandName":"zoledronic acid","genericName":"zoledronic acid","approvalYear":"2001","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT03530345","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Neridronic Acid in CRPS","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2018-05-30","conditions":["Complex Regional Pain Syndrome (CRPS)"],"enrollment":182,"completionDate":"2019-07-31"},{"nctId":"NCT03560986","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2018-05-31","conditions":["Complex Regional Pain Syndrome (CRPS)"],"enrollment":267,"completionDate":"2019-08-01"},{"nctId":"NCT02972359","phase":"PHASE3","title":"Safety of Intravenous Neridronic Acid in CRPS","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2016-12-20","conditions":["Complex Regional Pain Syndrome"],"enrollment":580,"completionDate":"2019-01-09"},{"nctId":"NCT02402530","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2015-04","conditions":["Complex Regional Pain Syndrome, Type I"],"enrollment":459,"completionDate":"2016-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"8U27U3RIN4","CHEBI":"CHEBI:135145","INN_ID":"6463","UMLSCUI":"C1882065","ChEMBL_ID":"CHEMBL55214","DRUGBANK_ID":"DB11620","PDB_CHEM_ID":"NRD","PUBCHEM_CID":"71237","MESH_SUPPLEMENTAL_RECORD_UI":"C053389"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Bone"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 May","pmid":"38506956","title":"Paget Disease of Bone Harboring Bone Metastatic Neuroendocrine Cancer: A Case Report.","journal":"Calcified tissue international"},{"date":"2020 May","pmid":"32176416","title":"Treatment with bisphosphonates to mitigate calcification of elastin-containing bioprosthetic materials.","journal":"Journal of biomedical materials research. Part A"},{"date":"2017 Nov","pmid":"29230158","title":"Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.","journal":"Molecular syndromology"},{"date":"2017 Mar","pmid":"27939801","title":"First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.","journal":"Joint bone spine"},{"date":"2009 Oct","pmid":"19761412","title":"Neridronic acid for the treatment of bone metabolic diseases.","journal":"Expert opinion on drug metabolism & toxicology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neridronate, also known as Neridronic Acid, is a small molecule drug that targets Farnesyl pyrophosphate synthase. It is classified as a neridronic acid and is used to treat Humoral hypercalcemia of malignancy and Osteoporosis. The commercial status of Neridronate is currently unknown, and it is not clear if it is patented or available as a generic. As a pharma professional, it is essential to consider the potential safety implications of Neridronate, although specific details are not available. Further research is necessary to fully understand the pharmacological properties of Neridronate.","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:42:13.989752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}